B
Bull
Bull · 25%MLTX
$48.66
Szenariopreis
$14.990
-0.522 (-3.48%)Zum Schluss
Loading chart…
- High
- 15.765
- Open
- 15.600
- VWAP
- 15.24
- Vol
- 700.46K
- Mkt Cap
- 2.62B
- Low
- 14.965
- Amount
- 10.68M
- EV/EBITDA, TTM
- 0.00
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
AI analysis of MoonLake Immunotherapeutics (MLTX)
holdMoonLake Immunotherapeutics is currently a hold. The stock is priced at $14.99, significantly below analyst price targets of $50 and $70, indicating potential upside. However, the RSI is at a low 22.34, suggesting oversold conditions but also a lack of momentum. The company reported a narrower loss of $0.84 per share against an expected loss of $0.93, which is a positive sign, yet the overall financial performance shows consistent losses, with a net income of -69,707,000 in Q1 2026. The main risk is the ongoing negative earnings trend, with a projected loss of -61,805,000 in Q2 2026.
Bewertungskennzahlen
The current forward P/E ratio for MoonLake Immunotherapeutics (MLTX) is 0.00, compared to its 5-year average forward P/E of -20.01.
Alphio AI Price Scenarios for MLTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MLTX
Event-Zeitleiste
News
9.508-10stocktwitsMoonLake Reports Positive Phase 3 Results and Narrower Q2 Loss
8.508-03stocktwitsMoonLake Immunotherapeutics Investor Day Highlights
8.507-13stocktwitsMerck's Key Drug Faces Patent Cliff Ahead
5.007-03FoolCFO Sells 39,120 Shares of MoonLake Immunotherapeutics
5.007-03NASDAQ.COMMoonLake CFO Sells Shares Amid Market Volatility
MLTX FAQ — answered by Alphio AI
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
MoonLake Immunotherapeutics is currently a hold. The stock is priced at $14.99, significantly below analyst price targets of $50 and $70, indicating potential upside. However, the RSI is at a low 22.34, suggesting oversold conditions but also a lack of momentum. The company reported a narrower loss of $0.84 per share against an expected loss of $0.93, which is a positive sign, yet the overall financial performance shows consistent losses, with a net income of -69,707,000 in Q1 2026. The main risk is the ongoing negative earnings trend, with a projected loss of -61,805,000 in Q2 2026.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.